Topics:
Breast Cancer • Medical Oncology • Her2+ • Journal Club ft. NEJM publications • Breast Cancer, Metastatic
Are there strategies to mitigate the risk of developing ILD/pneumonitis while using trastuzumab deruxtecan?
Although grade 3 toxicity rates were low, ~10.5% experience some degree of ILD, are there strategies to reduce risk before treatment starts?
Are there other toxicities of concern given anticipated long term use of therapy?
Answer from: Medical Oncologist at Community Practice
At the time being, we do not have specific strategies to mitigate the risk of developing ILD/pneumonitis while using T-DXd. In my opinion, we need prospective data to try to prevent this adverse event which has been reported in the range of 10.5% of patients. However, this event is not unique, and i...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
The most important strategy is global awareness of ILD as a potentially serious complication that may initially present with subtle signs - patients and all care team members must not only be aware but remind others in the patient/family care circle. This needs to be reinforced regularly. The recogn...